Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times
International Business Times
Business
Issam AHMED

REVEALED: Highly awaited alzheimer s drug hit by delays - The Real Truth

A health care worker (R) tends helps a patient with Alzheimer's eat lunch (Credit: AFP)

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Donanemab has been found to slow cognitive decline in the early stages of the disease during a clinical trial -- but there was also a high rate of side effects, including deaths.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.